GILEAD SCIENCES INC. news, videos and press releases
For more news please use our advanced search feature.
GILEAD SCIENCES INC. - More news...
GILEAD SCIENCES INC. - More news...
- European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
- Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
- Gilead Sciences to Present at Upcoming Investor Conferences
- The Centrifuge Sessions: How Gilead Sciences Is Impacting Autoimmune Disease
- U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
- IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC
- Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend
- Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results
- Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025
- Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
- Gilead Sciences to Present at Upcoming Investor Conference
- U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
- Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
- Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
- Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
- Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
- Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
- Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
- Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
- Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
- Gilead Sciences: Designing Inclusive Clinical Trials in an Effort To Upend the HIV Epidemic
- Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
- Gilead Prices $3.5 Billion of Senior Unsecured Notes
- Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
- Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
- Gilead Sciences to Present at Upcoming Investor Engagements
- Gilead Oncology Grant Supports 22 U.S. Organizations With $3.15 Million to Provide Support to Those Affected By Breast Cancer
- AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies
- Gilead Sciences: New Report Shows Every Country in the World Must Do More To End the HIV Epidemic
- Championing HIV Services for LGBTQ+ Youth
